KIT and gastrointestinal stromal tumor: Small-molecule tyrosine kinase inhibitors resemble adenosine triphosphate (ATP) structurally and competitively bind to the ATP-binding domain of KIT, thus contributing to good clinical efficacy in GIST patients harbouring constitutively phosphorylated KIT receptors (Apsel et al. 2019).